|
1
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Irritable Bowel Syndrome: Diagnosis, Pathogenesis and
Treatment Options. Nova Science Publishers Inc.; New York, NY:
2012
|
|
2
|
Spiller RC: Potential biomarkers.
Gastroenterol Clin North Am. 40:121–139. 2011. View Article : Google Scholar
|
|
3
|
Spiller R, Aziz Q, Creed F, et al;
Clinical Services Committee of The British Society of
Gastroenterology. Guidelines on the irritable bowel syndrome:
mechanisms and practical management. Gut. 56:1770–1798. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longstreth GF, Thompson WG, Chey WD,
Houghton LA, Mearin F and Spiller RC: Functional bowel disorders.
Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Drossman DA, Li Z, Andruzzi E, et al: U.S.
householder survey of functional gastrointestinal disorders.
Prevalence, sociodemography, and health impact. Dig Dis Sci.
38:1569–1580. 1993. View Article : Google Scholar
|
|
6
|
Thompson WG: A world view of IBS.
Irritable bowel syndrome: diagnosis and treatment. Camilleri M and
Spiller RC: Saunders; Philadelphia: pp. 17–26. 2002
|
|
7
|
Harvey RF, Mauad EC and Brown AM:
Prognosis in the irritable bowel syndrome: a 5-year prospective
study. Lancet. 1:963–965. 1987.PubMed/NCBI
|
|
8
|
Nørgaard M, Farkas DK, Pedersen L, et al:
Irritable bowel syndrome and risk of colorectal cancer: a Danish
nationwide cohort study. Br J Cancer. 104:1202–1206.
2011.PubMed/NCBI
|
|
9
|
Taupenot L, Harper KL and O’Connor DT: The
chromogranin-secretogranin family. N Engl J Med. 348:1134–1149.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiedenmann B and Huttner WB: Synaptophysin
and chromogranins/secretogranins - widespread constituents of
distinct types of neuroendocrine vesicles and new tools in tumor
diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121.
1989. View Article : Google Scholar
|
|
11
|
Deftos LJ: Chromogranin A: its role in
endocrine function and as an endocrine and neuroendocrine tumor
marker. Endocr Rev. 12:181–187. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El-Salhy M, Lomholt-Beck B and Hausken T:
Chromogranin A as a possible tool in the diagnosis of irritable
bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
El-Salhy M, Mazzawi T, Gundersen D and
Hausken T: Chromogranin A cell density in the rectum of patients
with irritable bowel syndrome. Mol Med Report. 6:1223–1225.
2012.PubMed/NCBI
|
|
14
|
El-Salhy M, Wendelbo IH and Gundersen D:
Reduced chromogranin A cell density in the ileum of patients with
irritable bowel syndrome. Mol Med Rep. 7:1241–1244. 2013.PubMed/NCBI
|
|
15
|
El-Salhy M, Seim I, Chopin L, Gundersen D,
Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of
gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Salhy M, Ostgaard H, Gundersen D,
Hatlebakk JG and Hausken T: The role of diet in the pathogenesis
and management of irritable bowel syndrome (Review). Int J Mol Med.
29:723–731. 2012.PubMed/NCBI
|
|
17
|
El-Salhy M and Mahdavi J: Image analysis
of the duodenal endocrine cells in mice with particular regard to
optic densitomertry. Uppsala J Med Sci. 102:175–184. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Salhy M: Ghrelin in gastrointestinal
diseases and disorders: a possible role in the pathophysiology and
clinical implications (review). Int J Mol Med. 24:727–732. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Salhy M, Lillebø E, Reinemo A and
Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int
J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dizdar V, Spiller R, Singh G, et al:
Relative importance of abnormalities of CCK and 5-HT (serotonin) in
Giardia-induced post-infectious irritable bowel syndrome and
functional dyspepsia. Aliment Pharmacol Ther. 31:883–891. 2010.
|
|
21
|
El-Salhy M, Vaali K, Dizdar V and Hausken
T: Abnormal small-intestinal endocrine cells in patients with
irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
El-Salhy M, Gundersen D, Ostgaard H,
Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of
serotonin and peptide YY cells in the colon of patients with
irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Salhy M, Gundersen D, Hatlebakk JG,
Gilja OH and Hausken T: Abnormal rectal endocrine cells in patients
with irritable bowel syndrome. Regul Pept. 188:60–65. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coates MD, Mahoney CR, Linden DR, et al:
Molecular defects in mucosal serotonin content and decreased
serotonin reuptake transporter in ulcerative colitis and irritable
bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar
|
|
25
|
Wang SH, Dong L, Luo JY, et al: Decreased
expression of serotonin in the jejunum and increased numbers of
mast cells in the terminal ileum in patients with irritable bowel
syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar
|
|
26
|
Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK
and Cho SW: The alteration of enterochromaffin cell, mast cell, and
lamina propria T lymphocyte numbers in irritable bowel syndrome and
its relationship with psychological factors. J Gastroenterol
Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park JH, Rhee PL, Kim G, et al:
Enteroendocrine cell counts correlate with visceral
hypersensitivity in patients with diarrhoea-predominant irritable
bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006.
View Article : Google Scholar
|
|
28
|
Kim HS, Lim JH, Park H and Lee SI:
Increased immunoendocrine cells in intestinal mucosa of
postinfectious irritable bowel syndrome patients 3 years after
acute Shigella infection - an observation in a small case control
study. Yonsei Med J. 51:45–51. 2010.
|
|
29
|
Dunlop SP, Coleman NS, Blackshaw E, et al:
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel
syndrome. Clin Gastroenterol Hepatol. 3:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Spiller RC, Jenkins D, Thornley JP, et al:
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and
increased gut permeability following acute Campylobacter enteritis
and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811.
2000. View Article : Google Scholar
|
|
31
|
Wang LH, Fang XC and Pan GZ: Bacillary
dysentery as a causative factor of irritable bowel syndrome and its
pathogenesis. Gut. 53:1096–1101. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dunlop SP, Jenkins D, Neal KR and Spiller
RC: Relative importance of enterochromaffin cell hyperplasia,
anxiety, and depression in postinfectious IBS. Gastroenterology.
125:1651–1659. 2003. View Article : Google Scholar : PubMed/NCBI
|
